Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9cUAB30 in Early Stage Breast Cancer
NCT02876640Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 9cUAB30 in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Absolute Change in Ki-67 Expression in Breast Epithelial Cells at 28 days. Started Mar 2018; status: terminated.
02
Drugs
9cUAB30
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02876640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876640.